1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,900 | 7,000 | 13:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.01. | SMAIO Reports 2025 Sales of €9.2m, Representing an Increase of +67% | 243 | Business Wire | U.S. sales rose by +138% to €7m, and by +160% to $7.9m (excluding currency effects).
Strong growth across North American centers that were already active in 2024 (+130%). 11 new... ► Artikel lesen | |
| 08.01. | SMAIO: 2026 Financial Calendar | 305 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics Euronext Growth Paris, ISIN: FR0014005I80 Ticker: ALSMA), a French-American player specialized in complex spine... ► Artikel lesen | |
| 06.01. | SMAIO Obtains €2.0m in Non-Dilutive Financing | 323 | Business Wire | €1.0m in the form of a 0% interest loan co-financed by the European Union, the Auvergne-Rhône-Alpes Region and Bpifrance, with a repayment deferral period of two and a half years €1.0m... ► Artikel lesen | |
| 19.12.25 | SMAIO Successfully Continues Its Think Tanks Focused on Promoting Its Innovative Solutions in the United States | 422 | Business Wire | New attendance record at the New York session, bringing together nearly 60 experts from the spine sector, including over 40 surgeons
Regulatory News:
SMAIO (Software, Machines and Adaptative... ► Artikel lesen | |
| 24.11.25 | SMAIO appoints Matthieu Ville as chief commercial officer | 8 | Investing.com | ||
| S.M.A.I.O SA Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment | 262 | Business Wire | Matthieu Ville brings over 15 years of experience in medical marketing in the United States.
Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics- Euronext Growth... ► Artikel lesen | |
| 03.11.25 | DALLAS - Dr. Tenner Guillaume joins SMAIO's US scientific advisory board | 4 | Investing.com | ||
| 03.11.25 | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 232 | Business Wire | Appointment of Dr. Tenner Guillaume, Orthopaedic spine surgeon who specializes in spinal deformity at Gillette Children's Hospital (St. Paul, Minnesota). SMAIO's US scientific advisory board... ► Artikel lesen | |
| 22.10.25 | SMAIO Signs a New Distribution Agreement for Its Open Platform KEOPS-4ME With Orthofix in the U.S. | 417 | Business Wire | Orthofix is a global medical technology company focused on healing musculoskeletal pathologies The distribution arrangement is part of SMAIO's collaborative strategy aimed at deploying... ► Artikel lesen | |
| 17.10.25 | SMAIO H1 Sales Increase | 1 | RTTNews | ||
| 14.10.25 | SMAIO Announces Strong First-Half 2025 Results and Robust Growth in Business Activity in the Third Quarter of 2025 | 270 | Business Wire | Strong sales growth in H1 2025: +126% to €5.0 million
Increase in gross margin in H1 2025 to 85% vs. 64% in H1 2024
Significant improvement in EBITDA (+96%) reaching break-even (vs.... ► Artikel lesen | |
| 24.09.25 | SMAIO Signs the First Major Distribution Agreement for Its Open Platform KEOPS-4ME with Highridge Medical in the U.S. | 358 | Business Wire | Highridge Medical is one of the world's largest privately held spine companies The partnership represents a key milestone in further expanding SMAIO's business activity in the U.S. and driving... ► Artikel lesen | |
| 16.07.25 | SMAIO Announces Significant Sales Increase in H1 2025 | 361 | Business Wire | Sales H1 2025: +126% to €5 million Acceleration of business activity in the United States (+360% to €3.8 million):
H1 2025 sales1 higher than full-year 2024 sales
More than... ► Artikel lesen | |
| 12.05.25 | SMAIO Announces the Finalization of a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 415 | Business Wire | The transaction was fully subscribed by NextStage AM, in accordance with the terms previously communicated
Regulatory News:
This press release may not be published, distributed or disseminated... ► Artikel lesen | |
| 15.04.25 | SMAIO Announces a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 592 | Business Wire | Regulatory News:
This press release may not be published, distributed or disseminated, directly or indirectly, in the United States of America or Canada, Australia, Japan or South Africa.
SMAIO... ► Artikel lesen | |
| 15.04.25 | SMAIO Announces Consolidated Results for 2024 and Record Sales Performance in Q1 2025 | 570 | Business Wire | Sharp increase in sales, up +114%1 to €5.5 million in 2024 and +140% to €2.5 million in Q1 2025
Improvement in the margin rate on implant sales to 79% in 2024, vs. 71% at the end of 2023... ► Artikel lesen | |
| 28.02.25 | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 537 | Business Wire | Appointment of Dr. Donald J. Blaskiewicz, neurosurgeon at St. Luke's Clinic in Boise (Idaho) SMAIO's U.S. scientific advisory board now includes three North American surgeons, and is set... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | Märkte am Morgen: Gold, Silber, Bitcoin, Amgen, Alphabet, AMD, SAP, Siemens Healthineers, BASF | Das Umfeld an den Aktienmärkten ist aktuell alles andere als einfach. Das hat sich gestern mal wieder deutlich gezeigt. Der DAX geriet nach guten Start unter Druck und schloss 0,72 Prozent tiefer bei... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | DAX-Check LIVE: Fresenius Medical Care, Nordex, Puma, Sartorius Vz., Schaeffler, Siltronic im Fokus | Ein kurzzeitiger Ausverkauf bei Gold und Silber hat den DAX zum Wochenstart zunächst belastet. Die Unsicherheit beruhigte sich jedoch im Tagesverlauf, auch unterstützt durch eine Erholung an den US-Märkten.... ► Artikel lesen | |
| FRESENIUS | 49,760 | +1,06 % | Fresenius: 2026 setzt sich das Wachstum fort | Am 25. Februar wird Fresenius Zahlen zum vierten Quartal publizieren. Die Analysten der DZ Bank rechnen mit einer soliden Entwicklung. Wachstumsinvestitionen bei Kabi dürften sich bei den Margen bemerkbar... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | Hims & Hers-Aktie -10%: Warum profitiert sie nicht? | Die Hims & Hers-Aktie schoss am gestrigen Donnerstag kurzfristig um über +10% in die Höhe, beendete den Handelstag dann aber doch mit einem Minus von fast -4%. Am Freitagmorgen bricht der Kurs der Gesundheitsplattform... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| RXSIGHT | 8,390 | +7,29 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen |
Das Unternehmen S.M.A.I.O SA kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,76 % bei einem Aktienkurs von 6,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu S.M.A.I.O SA finden Sie auf Wallstreet Online.